文献リスト

1）Piperno A, Trombini P, Gelosa M, et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens. 2002; 20: 1513-8

2）Iwasaki T, Nakajima A, Yoneda M, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care. 2005; 28: 2486-91

3）Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992; 86: 803-11

4）Lele S, Shah S, McCullough PA, et al. Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention. 2009; 5: 336-42

5）Menke A, Fernandez-Real JM, Muntner P, et al. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord. 2009; 9: 34

6）Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997; 96: 3300-7

7）Jiang R, Manson JE, Meigs JB, et al. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004; 291: 711-7

8）Sun L, Franco OH, Hu FB, et al. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly chinese. J Clin Endocrinol Metab. 2008; 93: 4690-6

9）Smith CP, Thevenod F. Iron transport and the kidney. Biochim Biophys Acta. 2009; 1790: 724-30

10）Garrick MD, Garrick LM. Cellular iron transport. Biochim Biophys Acta. 2009; 1790: 309-25

11）Veuthey T, D’Anna MC, Roque ME. Role of the kidney in iron homeostasis: renal expression of Prohepcidin, Ferroportin, and DMT1 in anemic mice. Am J Physiol Renal Physiol. 2008; 295: F1213-21

12）Wolff NA, Liu W, Fenton RA, et al. Ferroportin 1 is expressed basolaterally in rat kidney proximal tubule cells and iron excess increases its membrane trafficking. J Cell Mol Med. 2011; 15: 209-19

13）Kroot JJ, Tjalsma H, Fleming RE, et al. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011; 57: 1650-69

14）Kulaksiz H, Theilig F, Bachmann S, et al. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol. 2005; 184: 361-70

15）Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005; 115: 610-21

16）Paragas N, Qiu A, Hollmen M, et al. NGAL-Siderocalin in kidney disease. Biochim Biophys Acta. 2012; 1823: 1451-8

17）Paragas N, Qiu A, Zhang Q, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med. 2011; 17: 216-22

18）Langelueddecke C, Roussa E, Fenton RA, et al. Lipocalin-2〔24p3/neutrophil gelatinase-associated lipocalin (NGAL)〕receptor is expressed in distal nephron and mediates protein endocytosis. J Biol Chem. 2012; 287: 159-69

19）Jenkitkasemwong S, Wang CY, Mackenzie B, et al. Physiologic implications of metal-ion transport by ZIP14 and ZIP8. Biometals. 2012; 25: 643-55

20）Marzolo MP, Farfan P. New insights into the roles of megalin/LRP2 and the regulation of its functional expression. Biol Res. 2011; 44: 89-105

21）Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int. 2006; 70: 432-43

22）Khan AA, Quigley JG. Control of intracellular heme levels: heme transporters and heme oxygenases. Biochim Biophys Acta. 2011; 1813: 668-82

23）Tolosano E, Fagoonee S, Morello N, et al. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal. 2010; 12: 305-20

24）Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990; 186: 1-85

25）Johnson AC, Becker K, Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol. 2010; 299: F426-35

26）Ludwiczek S, Theurl I, Bahram S, et al. Regulatory networks for the control of body iron homeostasis and their dysregulation in HFE mediated hemochromatosis. J Cell Physiol. 2005; 204: 489-99

27）Wareing M, Ferguson CJ, Delannoy M, et al. Altered dietary iron intake is a strong modulator of renal DMT1 expression. Am J Physiol Renal Physiol. 2003; 285: F1050-9

28）Roudkenar MH, Kuwahara Y, Baba T, et al. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J Radiat Res. 2007; 48: 39-44

29）Otaki Y, Nakanishi T, Hasuike Y, et al. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis. 2004; 43: 1030-9

30）Nanami M, Ookawara T, Otaki Y, et al. Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005; 25: 2495-501

31）Kida A, Kuragano T, Furuta M, et al. Hemodialysis restored iron distribution that was sequestered in the spleen by bilateral nephrectomy. Am J Physiol Renal Physiol. 2014; 306: F1393-9

32）Nakanishi T, Kuragano T, Nanami M, et al. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010; 32: 439-46

33）Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl. 1999; 69: S35-43

34）Ashaye A, Gaziano J, Djousse L. Red meat consumption and risk of heart failure in male physicians. Nutr Metab Cardiovasc Dis. 2010

35）Depalma RG, Hayes VW, Chow BK, et al. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg. 2010; 51: 1498-503

36）Syrovatka P, Kraml P, Potockova J, et al. Relationship between increased body iron stores, oxidative stress and insulin resistance in healthy men. Ann Nutr Metab. 2009; 54: 268-74

37）Lee DH, Liu DY, Jacobs DR, Jr, et al. Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care. 2006; 29: 1090-5

38）Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol. 2002; 13: 734-44

39）Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16: 3070-80

40）Kovesdy CP, Estrada W, Ahmadzadeh S, et al. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 435-41

41）Collins AJ, Ma JZ, Constantini EG, et al. Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993. J Am Soc Nephrol. 1998; 9: 2108-17

42）Patruta SI, Horl WH. Iron and infection. Kidney Int Suppl. 1999; 69: S125-30

43）Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004; 65: 2279-89

44）Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int. 2006; 69: 1259-63

45）Akrawinthawong K, Shaw MK, Kachner J, et al. Urine catalytic iron and neutrophil gelatinase-associated lipocalin as companion early markers of acute kidney injury after cardiac surgery: a prospective pilot study. Cardiorenal Med. 2013; 3: 7-16

46）Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365: 1231-8

47）Mishra J, Ma Q, Kelly C, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol. 2006; 21: 856-63

48）Mishra J, Mori K, Ma Q, et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004; 24: 307-15

49）Nickolas TL, Forster CS, Sise ME, et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int. 2012; 82: 718-22

50）Woo KS, Choi JL, Kim BR, et al. Urinary neutrophil gelatinase-associated lipocalin levels in comparison with glomerular filtration rate for evaluation of renal function in patients with diabetic chronic kidney disease. Diabetes Metab J. 2012; 36: 307-13

51）Zaritsky J, Young B, Wang HJ, et al. Hepcidin－a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 1051-6

52）Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006; 108: 1381-7

53）Haase-Fielitz A, Mertens PR, Plass M, et al. Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study. Crit Care. 2011; 15: R186

54）Ho J, Reslerova M, Gali B, et al. Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol. 2011; 6: 2340-6

55）Hamada Y, Kono TN, Moriguchi Y, et al. Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. Nephrol Dial Transplant. 2008; 23: 1886-91

56）Ishizaka N, Aizawa T, Yamazaki I, et al. Abnormal iron deposition in renal cells in the rat with chronic angiotensin II administration. Lab Invest. 2002; 82: 87-96

57）Naito Y, Fujii A, Sawada H, et al. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypertens. 2012; 30: 2192-201

58）Naito Y, Fujii A, Sawada H, et al. Dietary iron restriction prevents further deterioration of renal damage in a chronic kidney disease rat model. J Hypertens. 2013; 31: 1203-13

59）Naito Y, Hirotani S, Sawada H, et al. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension. 2011; 57: 497-504

60）Naito Y, Sawada H, Oboshi M, et al. Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats. PLoS One. 2013; 8: e75906

61）Ikeda Y, Ozono I, Tajima S, et al. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction. PLoS One. 2014; 9: e89355

62）Ikeda Y, Enomoto H, Tajima S, et al. Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice. Am J Physiol Renal Physiol. 2013; 304: F1028-36

63）Matsumoto M, Sasaki N, Tsujino T, et al. Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat. Ren Fail. 2013; 35: 1156-62

64）Zou C, Xie R, Bao Y, et al. Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors. Endocrine. 2013; 44: 666-74

65）Facchini FS, Saylor KL. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes. 2003; 52: 1204-9

66）Paller MS. Hemoglobin and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol. 1988; 255: F539-44

67）Baliga R, Zhang Z, Baliga M, et al. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998; 53: 394-401

68）Priuska EM, Schacht J. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol. 1995; 50: 1749-52

69）Fukuda A, Osawa T, Oda H, et al. Oxidative stress response in iron-induced acute nephrotoxicity: enhanced expression of heat shock protein 90. Biochem Biophys Res Commun. 1996; 219: 76-81

70）Zager RA. Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest. 1992; 90: 711-9

71）Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest. 1988; 81: 334-41

72）Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004; 15: 3073-82

73）Viau A, El Karoui K, Laouari D, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010; 120: 4065-76

74）Zarjou A, Bolisetty S, Joseph R, et al. Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest. 2013; 123: 4423-34

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp